1.21

14.18% -0.20

After Hours: 1.21

Vaccinex Inc (VCNX)

Overview News Price History Financials Why VCNX Down? Discussions Forecast Stock Split

Vaccinex Inc stock is traded at $1.21, with a volume of 28,741. It is down -14.18% in the last 24 hours and down -67.39% over the past month. Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Previous Close:

$1.41

Open:

$1.09

24h Volume:

28,741

Relative Volume:

0.25

Market Cap:

$3.24M

Revenue:

Net Income/Loss:

$-22.01M

P/E Ratio:

-0.1833

EPS:

-6.6

Net Cash Flow:

$-18.31M

1W Performance:

-67.21%

1M Performance:

-67.39%

6M Performance:

-80.85%

1Y Performance:

-85.92%

1-Day Range:

$1.00

$1.36

1-Week Range:

$1.00

$4.04

52-Week Range:

$1.00

$13.02

Vaccinex Inc Stock (VCNX) Company Profile

Name

Vaccinex Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

585-271-2700

Address

1895 MOUNT HOPE AVE, ROCHESTER, NY

Employee

Twitter

@Vaccinex

Next Earnings Date

2024-11-11

Latest SEC Filings

VCNX's Discussions on Twitter

Compare VCNX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCNX Vaccinex Inc	1.21	3.24M	0	-22.01M	-18.31M	-85.40
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-23-20	Downgrade	BTIG Research	Buy → Neutral
Sep-04-18	Initiated	Ladenburg Thalmann	Buy

Vaccinex Inc Stock (VCNX) Latest News

Dec 19, 2024

Vaccinex Stock to Be Delisted From Nasdaq - Marketscreener.com

Dec 19, 2024

Vaccinex (OTC:VCNX) Stock Quotes, Forecast and News Summary - Benzinga

Dec 19, 2024

Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World

Dec 19, 2024

Dec 18, 2024

Vaccinex to be delisted from Nasdaq over equity shortfall By Investing.com - Investing.com South Africa

Dec 18, 2024

Dec 17, 2024

Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com India

Dec 17, 2024

Vaccinex Shares Tumble 63% On Nasdaq Delisting - MarketWatch

Dec 17, 2024

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62% - Yahoo Finance

Dec 17, 2024

Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com

Dec 17, 2024

Vaccinex Announces Receipt of Delisting Notification from Nasdaq - The Manila Times

Dec 17, 2024

Vaccinex Faces Nasdaq Delisting After Failing Minimum Equity Requirements, Moves to OTC Markets - StockTitan

Dec 17, 2024

Dec 04, 2024

Vaccinex (NASDAQ:VCNX) Trading 11.1% Higher – Time to Buy? - Defense World

Dec 04, 2024

Nov 18, 2024

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 18, 2024

Vaccinex Reports Promising Alzheimer's Drug Data, Raises $8.35M Amid Financial Challenges | VCNX Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Vaccinex secures $2.15 million in private placement - Investing.com

Nov 15, 2024